Comparing the current results to its competitors, Biohaven Ltd reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.87 %, recorded in the same quarter.
Biohaven Ltd , slower than the average decrease reported by the company's competitors of -6.32 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -6.32 %
Biohaven Ltd 's Comment on Competition and Industry Peers
The company is developing BHV-1400 and BHV-1300, with BHV-1400 demonstrating differentiation in the IgA nephropathy field. Its competitive landscape includes major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. The company competes with entities possessing greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may further intensify competition. Notably, Genmab A/S acquired Merus, resulting in the termination of three antibody-drug conjugates (ADCs).
September 9, 2025
Investor Alert: Biohaven Ltd. Faces Class Action Lawsuit Amid Declining Revenue and Market Challenges In a significant development for investors and stakeholders, Holzer and Holzer, LLC has released an investor alert concerning Biohaven Ltd. (NYSE: BHVN), revealing the impending lead plaintiff deadline in a class action lawsuit set for September 12, 2025. This announcement comes at a tumultuous time for Biohaven, which has recently experienced substantial operational and financial challenges that have raised concerns among investors and market analysts alike. Lawsuit DetailsThe class action lawsuit alleges that Biohaven’s leadership made materially false and misleading statements regarding the company’s ...
September 5, 2025
: This article provides an analysis of recent legal developments involving Biohaven Ltd., a pharmaceutical company embroiled in securities class actions. Two prominent law firms, Rosen Law Firm and Pomerantz LLP, are representing aggrieved investors. Key deadlines and critical insights into the ongoing investigations are discussed. This comprehensive overview serves to inform stakeholders within the pharmaceutical and investment sectors of the legal challenges and potential implications for the company. Biohaven Ltd. (NYSE: BHVN), a notable entity in the biopharmaceutical industry, has recently caught the attention of investors and legal professionals alike due to ongoing securities class action investigati...
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Belite Bio Inc's business model involves leveraging biotechnology to develop and commercialize innovative solutions for various industries. They focus on creating sustainable and environmentally friendly products by harnessing the power of natural biological processes.
Sources:
Biohaven Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biohaven Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
